Equillium, Inc. (0FY.F)
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
1.97+0.05%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+193.3%
The outlook
Equillium, Inc. currently reads as leaning bullish based on mixed vs its moving averages, 66% of the way from its 52-week low to high. This is a snapshot of current market data, not a forecast.
What’s behind the score
Price trendMixed vs its moving averages
52-week range66% of the way from its 52-week low to high
Market cap
$124.2M
52-wk high
2.81
52-wk low
0.32
50-day avg
2.32
200-day avg
1.55
Trailing P/E
—